Tradestie Institutional Equity Comparison Engine

MYGN vs QLTI โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MYGN Overall Edge

MYGN Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Myriad Genetics Inc (MYGN) driven by superior Valuation, Growth & Margin, Options & Structure while QLTI counters with relative strength in Momentum & Technical. Fundamentally, MYGN trades at 54.0x Forward P/E with -13.3% operating margin (-1.5% YoY revenue) versus QLTI at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, MYGN sits in SURGE (22nd %ile IV; Dealer Gamma Walls on Pro) against QLTI sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner MYGN
MYGN 54.0x vs QLTI N/M Fwd P/E
Growth & Margin Winner MYGN
Op Margin -13.3% vs N/A ยท YoY -1.5% vs N/A
Momentum & Technical Winner QLTI
1Y -12.3% vs +7.0% ยท 52W Pos 53% vs 86%
Options & Structure Winner MYGN
SURGE (22nd %ile IV) vs UNCLASSIFIED (N/A IV)
MYGN NASDAQ
Myriad Genetics Inc
In Vitro & In Vivo Diagnostic Substances
$5.57
-1.59% 1D
Market Cap $542.9M
1M Return +39.95%
1Y Return -12.28%
Forward P/E 54.0x
Unified AI Score
46.2 / 100 HOLD
Tech 30.0 Fund 43.0 Flow 56.0 Mom 50.0
QLTI NYSE Arca
GMO International Quality ETF
Institutional Equity
$28.11
-0.81% 1D
Market Cap N/A
1M Return +2.85%
1Y Return +6.95%
Forward P/E N/M
Unified AI Score
47.8 / 100 HOLD
Tech 50.0 Fund 35.0 Flow 50.0 Mom 11.1

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MYGN -12.28% QLTI +6.95% Spread: +20.35 pp (QLTI Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MYGN TTM Op. Margin: -13.3% QLTI TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MYGN vs QLTI. Trailing 12-month operating profitability (MYGN -13.3% vs QLTI N/A) and valuation multiples (MYGN 54.0x vs QLTI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MYGN (7) vs QLTI (3)
Institutional Metric MYGN QLTI Criterion Row Winner
Market Capitalization Scale $542.9M N/A Larger Scale MYGN
Trailing P/E Ratio Valuation 54.0x N/M Lower Multiple MYGN
Forward P/E Ratio Valuation 54.0x N/M Lower Multiple MYGN
Revenue Growth (YoY) Growth -1.5% N/A Higher Growth MYGN
Operating Margin (TTM) Profitability -13.3% N/A Higher Margin MYGN
Net Profit Margin Profitability -16.1% N/A Higher Margin MYGN
Return on Equity (ROE) Capital Efficiency -40.2% N/A Higher ROE MYGN
52-Week Range Position Momentum 53% ($3โ€“$8) 86% ($24โ€“$29) Stronger Trend QLTI
Beta / 30D Volatility Risk Regime 0.68ฮฒ ยท 122% Vol 0.81ฮฒ ยท 16% Vol Lower Realized Risk QLTI
Unified Institutional Score Composite Signal 46.2 / 100 (HOLD) 47.8 / 100 (HOLD) Higher Composite QLTI

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MYGN vs QLTI Buy Guide
MYGN SURGE
12d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 22nd %ile
IV Regime Compressed (<25th %ile)
Live MYGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
QLTI UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live QLTI Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MYGN nor QLTI registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.